NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Non-Small-Cell Lung

Countries: China

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Stage I-III at initial NSCLC diagnosis
* Aged ≥18 years at first diagnosis of NSCLC
* Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion Criteria:

* NSCLC is not the primary cancer diagnosis
* Patients with a recent history of other tumor or concurrent other tumor
* Patients participating in interventional clinical trials at time of initial diagnosis
* Patients with positive pregnancy status at the time of diagnosis

Locations (1)

Beijing, China